Does osimertinib/osimertinib need to be used in combination with other drugs?

In the treatment of advanced non-small cell lung cancer (NSCLC), Osimertinib/Osimertinib is commonly used as monotherapy and is considered first-line treatment in many cases. For patients with EGFR (epidermal growth factor receptor) mutation-positive NSCLC, osimertinib may be the only treatment option without the need for combination with other drugs. However, in some cases, doctors may consider combining treatment with other drugs, especially in patients who have developed drug resistance. For example, inEGFR In patients with T790M mutation-positive NSCLC, osimertinib may be considered in combination with other targeted therapies, such as third-generation EGFR inhibitors or immunotherapy drugs, to enhance the therapeutic effect. In addition, for patients with tumor recurrence or metastasis, other treatments such as chemotherapy or radiotherapy may be considered to prolong progression-free survival and overall survival.